Endogenous RGS protein action modulates mu-opioid signaling through Galphao. Effects on adenylyl cyclase, extracellular signal-regulated kinases, and intracellular calcium pathways.
about
Generation and characterization of Rgs4 mutant miceDiscovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptorRGS9-2: probing an intracellular modulator of behavior as a drug target.Differential modulation of mu- and delta-opioid receptor agonists by endogenous RGS4 protein in SH-SY5Y cellsEssential role for RGS9 in opiate actionμ-Opioid receptors and regulators of G protein signaling (RGS) proteins: from a symposium on new concepts in mu-opioid pharmacologyMolecular architecture of G o and the structural basis for RGS16-mediated deactivationRGS inhibition at G(alpha)i2 selectively potentiates 5-HT1A-mediated antidepressant effects.Gain-of-function mutation in Gnao1: a murine model of epileptiform encephalopathy (EIEE17)?Both ligand- and cell-specific parameters control ligand agonism in a kinetic model of g protein-coupled receptor signaling.A structural determinant that renders G alpha(i) sensitive to activation by GIV/girdin is required to promote cell migration.Differential modulation of mu-opioid receptor signaling to adenylyl cyclase by regulators of G protein signaling proteins 4 or 8 and 7 in permeabilised C6 cells is Galpha subtype dependent.Disruption of the Na+ ion binding site as a mechanism for positive allosteric modulation of the mu-opioid receptor.Pleiotropic phenotype of a genomic knock-in of an RGS-insensitive G184S Gnai2 alleleG protein independent phosphorylation and internalization of the delta-opioid receptor.Regulators of G protein signaling (RGS) proteins as drug targets: modulating G-protein-coupled receptor (GPCR) signal transductionDevelopment and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.Mu-opioid receptor desensitization: is morphine different?Modulation of μ-opioid receptor signaling by RGS19 in SH-SY5Y cells.α₂-Adrenoceptor functionality in postmortem frontal cortex of depressed suicide victims.Increased agonist affinity at the μ-opioid receptor induced by prolonged agonist exposure.Differential control of opioid antinociception to thermal stimuli in a knock-in mouse expressing regulator of G-protein signaling-insensitive Gαo proteinHypertensive state, independent of hypertrophy, exhibits an attenuated decrease in systolic function on cardiac kappa-opioid receptor stimulation.Regulator of G protein signaling protein suppression of Galphao protein-mediated alpha2A adrenergic receptor inhibition of mouse hippocampal CA3 epileptiform activityGNAI2 and regulators of G protein signaling as a potential Noonan syndrome mechanismRegulator of G protein signaling proteins differentially modulate signaling of mu and delta opioid receptors.Differential effect of membrane cholesterol removal on mu- and delta-opioid receptors: a parallel comparison of acute and chronic signaling to adenylyl cyclaseModulation of opioid receptor function by protein-protein interactions.Role of protein kinase C in functional selectivity for desensitization at the mu-opioid receptor: from pharmacological curiosity to therapeutic potential.RGS4 regulates partial agonism of the M2 muscarinic receptor-activated K+ currents.Galanin attenuates cyclic AMP regulatory element-binding protein (CREB) phosphorylation induced by chronic morphine and naloxone challenge in Cath.a cells and primary striatal cultures.Novel Molecular Strategies and Targets for Opioid Drug Discovery for the Treatment of Chronic Pain.Kappa and delta opioid receptor signaling is augmented in the failing heart.Impact of fusion to Gα(i2) and co-expression with RGS proteins on pharmacological properties of human cannabinoid receptors CB₁R and CB₂R.Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist propertiesCollision coupling, crosstalk, and compartmentalization in G-protein coupled receptor systems: can a single model explain disparate results?Potent biphalin analogs with µ/δ mixed opioid activity: in vivo and in vitro biological evaluation.Pharmacological Evidence for a Putative Conserved Allosteric Site on Opioid Receptors.Evaluation of the Selectivity and Cysteine Dependence of Inhibitors across the Regulator of G Protein-Signaling Family.Movement disorder in GNAO1 encephalopathy associated with gain-of-function mutations.
P2860
Q24523661-6B8B7A25-ADB6-4DD3-9383-81F87EB31E86Q24605838-4990215E-0B95-4A1E-8258-DCA5F4DB6978Q24632848-B74C0D87-6E14-4BD1-86C8-3EC332EE73F7Q24650065-D710C26D-30B8-4E44-9757-A6A7E9142BA8Q24655663-D878285E-27B4-4138-89BE-2BE1D41306D3Q26991859-04B53BFC-D738-41A6-89C4-D317D15DF6EAQ27650446-E61950B5-51E2-4052-B5DA-C394EC0A75F8Q30495060-CAB7E5B6-BBE9-4612-863E-EA781752D2D2Q30579638-04CA88E3-0315-40EC-BE35-7FEE2C9C1FB9Q33269156-911CD184-225A-4BB2-95CB-5B22498550EDQ33799957-09823F94-2167-42EC-BB41-32A8C3D33D40Q34162653-2D275326-AF05-449B-8136-91AD4D3B0564Q34793269-C815A2A9-FBBD-4B51-B7B2-113369BA9CFFQ35071259-FF7D69DB-5108-4F38-8710-D83781D7BAE6Q35212944-47CCD95F-126E-47E8-8005-75FBEDE1980FQ35523846-D164BCE6-3DE8-4075-9EF2-AAE4294D5FDDQ35621534-A3051DCA-0C3A-4EFE-BE65-18D219EC83DCQ35927616-3279402B-D93D-4169-91E1-43C4FB7081FEQ36573196-6EAFA44D-4EED-492A-8E13-4F0194842C90Q36583816-3F6D0EE8-A545-41C3-95C3-6C003DA9C3FBQ37014120-FEAC2D35-676F-4F0B-BCB6-1A8EE5488598Q37088994-6A0F13A1-067C-41BD-8087-90093828C872Q37162528-AD4F956F-5E58-418C-9690-3FB80377D52CQ37168374-810F3B04-D980-4FB4-8756-612B9692FDB1Q37171659-77455F6E-FD2E-47EC-AFDD-87EC276FC5F0Q37228167-9F85A1D9-CC78-443B-824C-28F835A87511Q37372214-52BA55F2-7B5E-4351-9317-A969E4CB215EQ37410471-8FB2AF3D-D514-482B-AD78-B2F460F49E77Q37589704-DC35B77F-A34F-4F1F-B224-952714A4968FQ37652030-9BC92EC1-9B25-4D5F-B1FA-ADAAEE41B2E2Q38316718-D4B7FFEB-3E46-4983-A251-8A15CCB093B6Q39157737-40DEFADD-E964-4D18-A16C-243A5149067FQ39301700-DD3A0795-2B59-4C07-A98B-B0783E7A1EEDQ39515353-488FF770-AA71-4B30-AD5F-C9C118FF9F50Q39793785-B7DA975A-2778-4658-8112-AB7CE8A5A23BQ42054026-C3D3F44F-C680-4CDA-9CF5-8B27B20A3CAEQ44344705-C60CE5A2-EB44-4FAB-8F38-62B165FA2C7EQ47301262-30ED3EC8-6C83-4483-8500-FC6D7E7DA9FDQ47626622-48C1683B-EE3F-4AC8-933C-FB7A32289CE0Q48023990-FF8557F2-6D76-4966-9474-E994B01AF452
P2860
Endogenous RGS protein action modulates mu-opioid signaling through Galphao. Effects on adenylyl cyclase, extracellular signal-regulated kinases, and intracellular calcium pathways.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Endogenous RGS protein action ...... ntracellular calcium pathways.
@en
type
label
Endogenous RGS protein action ...... ntracellular calcium pathways.
@en
prefLabel
Endogenous RGS protein action ...... ntracellular calcium pathways.
@en
P2093
P2860
P356
P1476
Endogenous RGS protein action ...... ntracellular calcium pathways.
@en
P2093
Charlotte Harrison
Huailing Zhong
John R Traynor
Mary J Clark
Richard R Neubig
P2860
P304
P356
10.1074/JBC.M208885200
P407
P577
2003-01-10T00:00:00Z